Development of self-nanoemulsifying drug delivery system for oral bioavailability enhancement of valsartan in beagle dogs
Z Li, W Zhang, Y Gao, R Xiang, Y Liu, M Hu… - Drug delivery and …, 2017 - Springer
Valsartan, an angiotensin II receptor antagonist, is widely used to treat high blood pressure
in the clinical setting. However, its poor water solubility results in the low oral bioavailability …
in the clinical setting. However, its poor water solubility results in the low oral bioavailability …
Development of self-nanoemulsifying drug delivery system for oral bioavailability enhancement of valsartan in beagle dogs
Z Li, W Zhang, Y Gao, R Xiang, Y Liu… - Drug delivery and …, 2017 - pubmed.ncbi.nlm.nih.gov
Valsartan, an angiotensin II receptor antagonist, is widely used to treat high blood pressure
in the clinical setting. However, its poor water solubility results in the low oral bioavailability …
in the clinical setting. However, its poor water solubility results in the low oral bioavailability …
Development of self-nanoemulsifying drug delivery system for oral bioavailability enhancement of valsartan in beagle dogs.
Z Li, W Zhang, Y Gao, R Xiang, Y Liu, M Hu… - Drug Delivery and …, 2017 - europepmc.org
Valsartan, an angiotensin II receptor antagonist, is widely used to treat high blood pressure
in the clinical setting. However, its poor water solubility results in the low oral bioavailability …
in the clinical setting. However, its poor water solubility results in the low oral bioavailability …
Development of self-nanoemulsifying drug delivery system for oral bioavailability enhancement of valsartan in beagle dogs
Z Li, W Zhang, Y Gao, R Xiang, Y Liu, M Hu… - Drug Delivery and …, 2016 - infona.pl
Valsartan, an angiotensin II receptor antagonist, is widely used to treat high blood pressure
in the clinical setting. However, its poor water solubility results in the low oral bioavailability …
in the clinical setting. However, its poor water solubility results in the low oral bioavailability …